S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer|
|FDA Approves Baxter’s HYQVIA for Treatment of Adults with Primary Immunodeficiency|
|FDA Advisory Committee Panel Provides Favorable Recommendation on Baxter’s HyQvia for Primary Immunodeficiency|
|Angel Group Investing Heats Up|
|Angel Group Valuations Continue Three-Quarter Climb|
|FEI Adds Phase Plate Technology and Titan Halo TEM to Its Structural Biology Product Portfolio|
|SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer|
|Halozyme Reports Second Quarter 2014 Financial Results|
|Halozyme's PEGPH20 Program In Metastatic Pancreatic Cancer Receives Fast Track Designation|
|Halozyme Receives Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer|
Click above to view more mutual fund data and stats for halo - Halozyme Therapeutics Inc.